Kisspeptin-10 Dosage Calculator and Reconstitution Chart
A ten-amino-acid fragment of kisspeptin studied in humans almost entirely as an intravenous infusion in physiology experiments lasting hours. It is in FDA 503A Category 2, and it is prohibited in sport at all times.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
Not approved anywhere, and in FDA 503A Category 2
Kisspeptin-10 was placed in 503A Category 2 — bulk drug substances that raise significant safety risks — on 29 September 2023, and it is still there on the list updated 14 May 2026 and on the FDA's safety-risk page updated 22 April 2026. Unlike most peptides on this site, its nomination was not withdrawn: it remains listed. The FDA's stated reason, in full, is that “Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.” Category 2 substances cannot lawfully be used in 503A compounding unless the FDA authorises them by rulemaking, which has not happened. There is no approved kisspeptin product in any country.
No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.
Anti-doping: Prohibited at all times, and named on the list. The 2026 WADA Prohibited List names kisspeptin explicitly. Section S2.2.1, “Testosterone-stimulating peptides in males”, lists chorionic gonadotrophin, luteinizing hormone, GnRH and its agonist analogues, and “kisspeptin and its agonist analogues”. Everything in class S2 is a non-Specified Substance and is prohibited both in and out of competition. The prohibition is written for males; the naming of kisspeptin itself covers the -10 fragment as an agonist of the same receptor.
Key facts
- Molecular weight
- 1,302.4 DaPubChem CID 25240297, C63H83N17O14, for the free peptide. Kisspeptin-54 is a different and much larger molecule and its figures do not transfer. Retail vials are usually an acetate salt, which adds a variable amount of acetate mass.
- Half-life
- About 4 minutes in plasma — roughly a sixth that of kisspeptin-54 (27.6 ± 1.1 min)
- Also sold as
- KP-10, metastin 45-54, kisspeptin 112-121, kisspeptin-10 acetate
Doses used in published studies
These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.
How good is the evidence?
Real human data, in a form almost nobody selling it acknowledges. Kisspeptin-10 has been given to healthy volunteers in several well-conducted academic studies, and the endocrine effect is not in doubt: an intravenous bolus raises LH within minutes. But every one of those studies was a physiology experiment measuring hormones over hours, not a treatment trial measuring an outcome, and the groups were tiny — four to thirteen people per arm. The doses were intravenous boluses or timed infusions in µg/kg or nmol/kg, calibrated to a research clock, because the peptide is cleared in about four minutes. No trial has tested kisspeptin-10 as a treatment for infertility, low testosterone, libido or anything else; the fertility work that reached a clinical endpoint used kisspeptin-54, a different molecule, in an IVF setting. Nothing in the record establishes what repeated self-administration over weeks does, beyond a single 2026 study that ran twelve days in seven men under continuous infusion.
Kisspeptin-10 dosage: what the studies actually used
Human kisspeptin-10 doses are published in µg/kg or nmol/kg, and almost all of them are intravenous. The dose-response work in men used single intravenous boluses from 0.01 to 3.0 µg/kg, with the largest LH response at 1 µg/kg and a smaller response at 3 µg/kg. Sustained effects came from infusions — 1.5 or 4 µg/kg per hour, or 0.1 to 1.0 nmol/kg per hour — delivered by pump for three to 22.5 hours.
The reason the literature is written in infusion rates rather than injections is pharmacokinetic. Kisspeptin-10's plasma half-life is about four minutes, roughly a sixth of kisspeptin-54's 27.6 minutes. A single bolus produces one LH pulse and about 17 minutes of GnRH release, then it is over. Any regimen aiming at a sustained hormonal effect has to be continuous, which is what the 2026 twelve-day study did with a subcutaneous pump.
Subcutaneous bolus data in humans is a single data point: up to 32 nmol/kg given to women in the follicular phase, which produced no change in gonadotrophins at all. That is the entire published record for a subcutaneous kisspeptin-10 injection.
Kisspeptin-10 and kisspeptin-54 are not interchangeable
Much of what circulates as “kisspeptin dosing” is taken from kisspeptin-54 studies and reattached to a kisspeptin-10 vial. They are different molecules with different clearance. The fertility result people cite — kisspeptin triggering egg maturation in IVF — is kisspeptin-54: Jayasena et al. gave 53 women a single subcutaneous injection of 1.6 to 12.8 nmol/kg after superovulation, retrieved eggs 36 hours later, and reported a 23% clinical pregnancy rate. That trial says nothing about what a kisspeptin-10 vial does.
The same applies to the earlier human work. Dhillo et al. gave six men a 90-minute intravenous infusion of kisspeptin-54 in 2005, and gave women subcutaneous boluses of 0.2 to 6.4 nmol/kg in 2007. Those are -54 doses. When kisspeptin-10 and kisspeptin-54 were finally compared head-to-head by intravenous infusion at matched nmol/kg/h rates in 2015, they produced similar gonadotrophin responses — but that equivalence was established for infusion, at matched molar rates, and does not license copying a -54 subcutaneous bolus onto a -10 syringe.
Why this page publishes no kisspeptin-10 dosing schedule
A dosing schedule is a claim that someone established how much, how often and for how long, in a defined population, with a measured outcome and a safety margin. For kisspeptin-10 nobody has. Every human study above measured hormone concentrations over hours in four to fifteen people. None measured fertility, testosterone maintenance, body composition or sexual function as a treatment outcome. The FDA's own position is that it lacks sufficient information to know whether a compounded kisspeptin-10 product would cause harm when administered to humans.
The calculator on this page therefore does one narrow job: it converts the milligrams stated on a vial and the volume of liquid added into a concentration, a volume in millilitres and a mark on a U-100 syringe. Its default figures are arithmetic examples. They are not a dose, and the published-study table is kept separate so that the two cannot be confused for one another.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorFDACertain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- ReferenceNIH / National Center for Biotechnology InformationPubChem compound records (molecular weights and formulae)
- Published studyJournal of Clinical Endocrinology & Metabolism· 2011-08George JT et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
- Published studyJournal of Clinical Endocrinology & Metabolism· 2011-12Jayasena CN et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans
- Published studyJournal of Clinical Endocrinology & Metabolism· 2011-06Chan YM et al. Kisspeptin resets the hypothalamic GnRH clock in men
- Published studyJournal of Clinical Endocrinology & Metabolism· 2012-08Chan YM et al. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle
- Published studyHuman Reproduction· 2015-08Jayasena CN et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men
- Published studyEuropean Journal of Endocrinology· 2026-08Yeung AC et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men
- Published studyJournal of Clinical Endocrinology & Metabolism· 2005-12Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males
- Published studyJournal of Clinical Endocrinology & Metabolism· 2007-10Dhillo WS et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women
- Published studyJournal of Clinical Investigation· 2014-08Jayasena CN et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
- Published studyJournal of Chromatography B· 2013-05Liu Z et al. LC–MS/MS quantification of kisspeptin-10 (NSC 741805), its decomposition product and pharmacokinetics in rats